Developer docs
API playgroundTry for free, no card

Search company profiles

Codexis

Full company profile

uuid000684y

Namestring
Codexis
Legal namestring
Codexis, Inc.
Websiteurl
codexis.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

Codexis (NASDAQ: CDXS) is a publicly traded biosciences company founded in 2002 and headquartered in Redwood City, California, that engineers enzymes for pharmaceutical manufacturing and therapeutic applications. The company operates two proprietary technology platforms: CodeEvolver, an AI/ML-driven enzyme engineering platform that integrates machine learning, bioinformatics, and high-throughput screening with 20+ years of proprietary training data to design, build, and test enzyme variants in as little as one week; and ECO Synthesis, an enzymatic RNA manufacturing platform that replaces traditional solid-phase oligonucleotide synthesis (SPOS) with sequential enzymatic synthesis and ligation-based assembly workflows under aqueous conditions, achieving 99% coupling efficiency, greater than 75% yield, and greater than 90% purity.

The company monetizes through multiple revenue streams including direct enzyme product sales (screening kits such as Codex ATA, KRED, Esterase, ERED, NIT, and MicroCyp panels), pharma biocatalysis services for API synthesis, RNA manufacturing services for therapeutic oligonucleotides (siRNA, gRNA, ASOs) including preclinical and GLP/clinical supply, technology licensing and transfer agreements, and supply assurance agreements. Its go-to-market is enterprise field sales supported by dedicated technical program managers, with active industry conference presence (TIDES USA/Europe, CPHI Europe, RNA Leaders USA Congress) and a global CDMO partner network for scaled GMP manufacturing capacity. Primary customer segments are pharmaceutical and biotech RNA therapeutics developers, pharmaceutical API manufacturers, and molecular biology/diagnostics companies. Notable commercial relationships include a $37.8 million Supply Assurance and Technology Transfer Agreement with Merck executed in Q4 2025 and evaluation agreements with Axolabs and Nitto Denko Avecia.

Recent strategic activity includes a November 2025 leadership transition (Alison Moore from CTO to CEO, Stephen Dilly to Executive Chairman, Georgia Erbez adding Chief Business Officer duties), a roughly 24% workforce reduction, and significant capital deployment into GMP manufacturing infrastructure (34,000-square-foot Hayward, California facility opening late 2027 with approximately $20-25 million planned investment). The company holds 250+ patents, has supported 16+ approved drugs with its enzymes, and operates under ISO 9001:2015 certification at its Redwood City headquarters.

Short descriptiontext

Codexis (NASDAQ: CDXS) is a publicly traded enzyme engineering company that uses its CodeEvolver AI/ML platform and ECO Synthesis enzymatic RNA manufacturing platform to provide biocatalysis and siRNA manufacturing services to pharmaceutical, biotech, and diagnostics companies worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
enzyme engineering platform, RNA manufacturing services, pharmaceutical biocatalysis, oligonucleotide synthesis, custom enzyme development
Industry3 codes
PRIMARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Enzyme Biocatalysis Services
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1RNA Manufacturing Services
TypeTransaction Fee
Description

Contract manufacturing of therapeutic oligonucleotides (siRNA) using ECO Synthesis platform for preclinical, GLP, and clinical supply. Revenue recognized from production contracts and CDMO agreements.

biospace.com
2Enzyme Products and Biocatalysis Services
TypeTransaction Fee
Description

Sale of engineered enzymes including screening kits, tailored enzymes, and bespoke enzyme development services for pharmaceutical biocatalysis applications.

codexis.com
3Technology Licensing and Transfer
TypeLicensing Royalties
Description

Technology transfer agreements and licensing deals including $37.8 million agreement with Merck. Platform licensing for ECO Synthesis manufacturing.

biospace.com
4Supply Assurance Agreements
TypeManaged Services
Description

Supply assurance agreements providing revenue visibility and long-term partnerships with pharmaceutical companies for enzyme and RNA manufacturing supply.

codexis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Codexis engineers custom enzymes and provides manufacturing services for pharmaceuticals using two proprietary platforms: the CodeEvolver enzyme engineering platform (ML-driven protein optimization) and the ECO Synthesis enzymatic RNA manufacturing platform. The company sells off-the-shelf enzyme screening kits, delivers tailored enzyme engineering and scale-up services for pharmaceutical API biocatalysis, and provides RNA manufacturing services (sequential enzymatic synthesis and ligation-based assembly) for therapeutic oligonucleotides including siRNA, gRNA, and ASOs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 99% average coupling efficiency demonstrated across enzymatic sequential synthesis cycles
+7 more records
Product overview1 text field

Codexis is an enzyme engineering company offering two proprietary technology platforms—the CodeEvolver Platform for enzyme engineering powered by machine learning and the ECO Synthesis Platform for RNA manufacturing—alongside specialized service offerings. The portfolio includes RNA Manufacturing Services (encompassing RNA Ligation Services and RNA Sequential Synthesis Services), Pharma Biocatalysis (including Enzyme Screening Kits and Tailored Enzymes), and Molecular Biology and Diagnostic Applications (comprising Bespoke Enzymes and R&D Enzyme Services). Codexis has supported 16+ approved drugs with its enzymes and holds 250+ patents worldwide.

Product and service11 records
1ECO Synthesis Manufacturing Platform
CategoryPlatform
Description

Enzymatic RNA manufacturing platform that replaces traditional solid-phase oligonucleotide synthesis, enabling scalable, sustainable production of siRNA therapeutics through sequential enzymatic synthesis and ligation-based assembly workflows. Used by pharmaceutical and biotech companies developing RNA-based therapeutics.

2CodeEvolver Technology Platform
CategoryPlatform
Description

Proprietary enzyme engineering platform integrating machine learning, bioinformatics, and high-throughput screening for rapid design and optimization of enzymes for pharmaceutical manufacturing, RNA, and diagnostic applications. Trained on 20+ years of proprietary experimental data.

3RNA Manufacturing Services
CategoryService
Description

Enzyme-powered RNA manufacturing services enabling scalable, sustainable synthesis of therapeutic RNA including siRNA, gRNA, and ASOs through the ECO Synthesis platform. Provides preclinical, GLP, and clinical supply from grams to 10+ kg per run.

4RNA Ligation Services
CategoryService
Description

AI/ML-enabled ligation fragment design and bespoke ligase variant screening for scalable assembly of longer RNA constructs from shorter fragments, delivering >75% yield and >90% purity. Joins short ssRNA fragments into full dsRNA duplexes using engineered dsRNA ligases.

5RNA Sequential Synthesis Services
CategoryService
Description

Enzymatic sequential synthesis service building RNA strands one nucleotide at a time under mild aqueous conditions, achieving 99% average coupling efficiency and compatibility with modified nucleotides (2'-OMe, 2'-F, PS chemistries).

6Pharma Biocatalysis
CategoryService
Description

Enzyme-enabled manufacturing solutions for pharmaceutical active ingredient synthesis, transforming resource-intensive chemical steps into efficient, scalable, and sustainable enzymatic processes from grams to tonnes.

7Enzyme Screening Kits and Panels
CategoryProduct kit
Description

Off-the-shelf enzyme screening kits including Codex ATA (24 amine transaminases), Codex KRED (24 ketoreductases), Codex Esterase (12 esterases), Codex ERED (7 ene reductases), Codex NIT (12 nitrilases), and MicroCyp Screening Kits for rapid feasibility evaluation.

8Tailored Enzymes
CategoryService
Description

Custom enzyme engineering and scale-up services for pharmaceutical manufacturing, supporting API development from enzyme screening through commercial supply with CodeEvolver-powered optimization.

9Molecular Biology and Diagnostic Applications
CategoryService
Description

Precision-tuned enzyme solutions for molecular biology and diagnostic applications, offering bespoke enzymes and R&D enzyme services with improved fidelity, selectivity, and activity.

10Bespoke Enzymes
CategoryProduct
Description

Precision-optimized custom enzymes engineered for molecular biology and diagnostic applications, solving challenges that off-the-shelf enzymes cannot address with enhanced fidelity, activity, and performance.

11R&D Enzyme Services
CategoryService
Description

End-to-end enzyme evolution services from screening to engineering and scale-up, including assay adaptation and process development for molecular biology and diagnostic applications.

Scale indicator18 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-09
Description

Partnership where Axolabs will evaluate Codexis ECO Synthesis Manufacturing Platform for enzymatic RNA synthesis. Collaboration aims to develop efficient and scalable methods for therapeutic oligonucleotide manufacturing with potential for future licensing.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

$37.8 million Supply Assurance Agreement plus Technology Transfer Agreement executed in Q4 2025. Represents major commercial validation of Codexis enzyme manufacturing capabilities.

3Nitto Denko Avecia
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-29
Description

Evaluation agreement to explore Codexis ECO Synthesis Manufacturing Platform for therapeutic siRNA manufacturing. Collaboration aims to expand platform adoption and facilitate licensing discussions.

prnewswire.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Twist Bioscience is a leading DNA synthesis and synthetic biology provider serving pharma and biotech customers with high-throughput oligo production, broadly comparable to Codexis's nucleic acid manufacturing and enzyme-enabled service business.

TypeDirect peer
Description

Camena Bioscience is building enzymatic DNA synthesis (gSynth) for high-fidelity gene and oligonucleotide manufacturing, overlapping with Codexis's ECO Synthesis value proposition for scalable, sustainable nucleic acid production.

TypeBroad incumbent
Description

Thermo Fisher operates a global life sciences tools and pharma services/CDMO business (including oligonucleotide manufacturing through Patheon), making it a broad incumbent competing with Codexis in nucleic acid manufacturing and pharmaceutical services.

4Nitto Denko Avecia
TypeDirect peer
Description

Avecia (Nitto Denko Avecia) is a CDMO specializing in therapeutic oligonucleotide manufacturing (including siRNA), making it both a partner evaluating ECO Synthesis and a direct manufacturing-services competitor in RNA therapeutics.

5DNA Script
TypeDirect peer
Description

DNA Script develops enzymatic DNA and RNA synthesis platforms (Syntax platform) targeting research and therapeutic oligo manufacturing, directly competing with Codexis's ECO Synthesis on enzymatic synthesis speed, length, and quality.

TypeBroad incumbent
Description

Novonesis is a global enzyme engineering and production leader; while focused on industrial enzymes, its scale in protein engineering provides a broad competitive reference point for Codexis's CodeEvolver-driven enzyme business.

TypeDirect peer
Description

Ansa Biotechnologies is developing enzymatic DNA synthesis technology aimed at long, high-fidelity oligonucleotide assembly, directly competing with Codexis's ECO Synthesis platform on enzymatic nucleic acid manufacturing for therapeutics.

8GenScript Biotech
TypeDirect peer
Description

GenScript provides gene synthesis, oligonucleotide manufacturing, and protein/biocatalysis services to pharma and biotech customers, comparable to Codexis's tailored enzymes, screening kits, and custom oligo manufacturing offerings.

TypeDirect peer
Description

Axolabs is a CDMO focused on oligonucleotide-based therapeutics (siRNA, antisense, aptamers) and recently signed an evaluation agreement with Codexis; it is a direct peer in commercial-scale therapeutic RNA manufacturing services.

TypeDirect peer
Description

Molecular Assemblies is pioneering terminator-free enzymatic DNA synthesis using proprietary polymerases, pursuing the same enzymatic alternative-to-SPOS positioning as Codexis's ECO Synthesis platform for therapeutic and synthetic biology applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Codexis

Enzyme Biocatalysis Servicescodexis.com

Codexis (NASDAQ: CDXS) is a publicly traded enzyme engineering company that uses its CodeEvolver AI/ML platform and ECO Synthesis enzymatic RNA manufacturing platform to provide biocatalysis and siRNA manufacturing services to pharmaceutical, biotech, and diagnostics companies worldwide.

What Codexis does

Codexis (NASDAQ: CDXS) is a publicly traded biosciences company founded in 2002 and headquartered in Redwood City, California, that engineers enzymes for pharmaceutical manufacturing and therapeutic applications. The company operates two proprietary technology platforms: CodeEvolver, an AI/ML-driven enzyme engineering platform that integrates machine learning, bioinformatics, and high-throughput screening with 20+ years of proprietary training data to design, build, and test enzyme variants in as little as one week; and ECO Synthesis, an enzymatic RNA manufacturing platform that replaces traditional solid-phase oligonucleotide synthesis (SPOS) with sequential enzymatic synthesis and ligation-based assembly workflows under aqueous conditions, achieving 99% coupling efficiency, greater than 75% yield, and greater than 90% purity.

The company monetizes through multiple revenue streams including direct enzyme product sales (screening kits such as Codex ATA, KRED, Esterase, ERED, NIT, and MicroCyp panels), pharma biocatalysis services for API synthesis, RNA manufacturing services for therapeutic oligonucleotides (siRNA, gRNA, ASOs) including preclinical and GLP/clinical supply, technology licensing and transfer agreements, and supply assurance agreements. Its go-to-market is enterprise field sales supported by dedicated technical program managers, with active industry conference presence (TIDES USA/Europe, CPHI Europe, RNA Leaders USA Congress) and a global CDMO partner network for scaled GMP manufacturing capacity. Primary customer segments are pharmaceutical and biotech RNA therapeutics developers, pharmaceutical API manufacturers, and molecular biology/diagnostics companies. Notable commercial relationships include a $37.8 million Supply Assurance and Technology Transfer Agreement with Merck executed in Q4 2025 and evaluation agreements with Axolabs and Nitto Denko Avecia.

Recent strategic activity includes a November 2025 leadership transition (Alison Moore from CTO to CEO, Stephen Dilly to Executive Chairman, Georgia Erbez adding Chief Business Officer duties), a roughly 24% workforce reduction, and significant capital deployment into GMP manufacturing infrastructure (34,000-square-foot Hayward, California facility opening late 2027 with approximately $20-25 million planned investment). The company holds 250+ patents, has supported 16+ approved drugs with its enzymes, and operates under ISO 9001:2015 certification at its Redwood City headquarters.

Codexis firmographics

Firmographics
Name
Codexis
Legal name
Codexis, Inc.
Website
https://codexis.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
Codexis (NASDAQ: CDXS) is a publicly traded enzyme engineering company that uses its CodeEvolver AI/ML platform and ECO Synthesis enzymatic RNA manufacturing platform to provide biocatalysis and siRNA manufacturing services to pharmaceutical, biotech, and diagnostics companies worldwide.
Ownership category
akta.pro rank

Codexis industry classification

Industry
Product category
Enzyme Biocatalysis Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Enzyme engineering platform
  • RNA manufacturing services
  • Pharmaceutical biocatalysis
  • Oligonucleotide synthesis
  • Custom enzyme development

Where Codexis is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Codexis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. RNA Manufacturing Services: Contract manufacturing of therapeutic oligonucleotides (siRNA) using ECO Synthesis platform for preclinical, GLP, and clinical supply. Revenue recognized from production contracts and CDMO agreements.
  2. Enzyme Products and Biocatalysis Services: Sale of engineered enzymes including screening kits, tailored enzymes, and bespoke enzyme development services for pharmaceutical biocatalysis applications.
  3. Technology Licensing and Transfer: Technology transfer agreements and licensing deals including $37.8 million agreement with Merck. Platform licensing for ECO Synthesis manufacturing.
  4. Supply Assurance Agreements: Supply assurance agreements providing revenue visibility and long-term partnerships with pharmaceutical companies for enzyme and RNA manufacturing supply.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Codexis product offering

Product offering

Core offering

Codexis engineers custom enzymes and provides manufacturing services for pharmaceuticals using two proprietary platforms: the CodeEvolver enzyme engineering platform (ML-driven protein optimization) and the ECO Synthesis enzymatic RNA manufacturing platform. The company sells off-the-shelf enzyme screening kits, delivers tailored enzyme engineering and scale-up services for pharmaceutical API biocatalysis, and provides RNA manufacturing services (sequential enzymatic synthesis and ligation-based assembly) for therapeutic oligonucleotides including siRNA, gRNA, and ASOs.

Product overview

Codexis is an enzyme engineering company offering two proprietary technology platforms—the CodeEvolver Platform for enzyme engineering powered by machine learning and the ECO Synthesis Platform for RNA manufacturing—alongside specialized service offerings. The portfolio includes RNA Manufacturing Services (encompassing RNA Ligation Services and RNA Sequential Synthesis Services), Pharma Biocatalysis (including Enzyme Screening Kits and Tailored Enzymes), and Molecular Biology and Diagnostic Applications (comprising Bespoke Enzymes and R&D Enzyme Services). Codexis has supported 16+ approved drugs with its enzymes and holds 250+ patents worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • ECO Synthesis Manufacturing Platform Enzymatic RNA manufacturing platform that replaces traditional solid-phase oligonucleotide synthesis, enabling scalable, sustainable production of siRNA therapeutics through sequential enzymatic synthesis and ligation-based assembly workflows. Used by pharmaceutical and biotech companies developing RNA-based therapeutics.
  • CodeEvolver Technology Platform Proprietary enzyme engineering platform integrating machine learning, bioinformatics, and high-throughput screening for rapid design and optimization of enzymes for pharmaceutical manufacturing, RNA, and diagnostic applications. Trained on 20+ years of proprietary experimental data.
  • RNA Manufacturing Services Enzyme-powered RNA manufacturing services enabling scalable, sustainable synthesis of therapeutic RNA including siRNA, gRNA, and ASOs through the ECO Synthesis platform. Provides preclinical, GLP, and clinical supply from grams to 10+ kg per run.
  • RNA Ligation Services AI/ML-enabled ligation fragment design and bespoke ligase variant screening for scalable assembly of longer RNA constructs from shorter fragments, delivering >75% yield and >90% purity. Joins short ssRNA fragments into full dsRNA duplexes using engineered dsRNA ligases.
  • RNA Sequential Synthesis Services Enzymatic sequential synthesis service building RNA strands one nucleotide at a time under mild aqueous conditions, achieving 99% average coupling efficiency and compatibility with modified nucleotides (2'-OMe, 2'-F, PS chemistries).
  • Pharma Biocatalysis Enzyme-enabled manufacturing solutions for pharmaceutical active ingredient synthesis, transforming resource-intensive chemical steps into efficient, scalable, and sustainable enzymatic processes from grams to tonnes.
  • Enzyme Screening Kits and Panels Off-the-shelf enzyme screening kits including Codex ATA (24 amine transaminases), Codex KRED (24 ketoreductases), Codex Esterase (12 esterases), Codex ERED (7 ene reductases), Codex NIT (12 nitrilases), and MicroCyp Screening Kits for rapid feasibility evaluation.
  • Tailored Enzymes Custom enzyme engineering and scale-up services for pharmaceutical manufacturing, supporting API development from enzyme screening through commercial supply with CodeEvolver-powered optimization.
  • Molecular Biology and Diagnostic Applications Precision-tuned enzyme solutions for molecular biology and diagnostic applications, offering bespoke enzymes and R&D enzyme services with improved fidelity, selectivity, and activity.
  • Bespoke Enzymes Precision-optimized custom enzymes engineered for molecular biology and diagnostic applications, solving challenges that off-the-shelf enzymes cannot address with enhanced fidelity, activity, and performance.
  • R&D Enzyme Services End-to-end enzyme evolution services from screening to engineering and scale-up, including assay adaptation and process development for molecular biology and diagnostic applications.

Quantifiable outcome

  • 99% average coupling efficiency demonstrated across enzymatic sequential synthesis cycles
  • +7 more outcomes

Companies that use Codexis

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Codexis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Codexis partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • AxolabscoreTechnology or Integration · 9 January 2026Partnership where Axolabs will evaluate Codexis ECO Synthesis Manufacturing Platform for enzymatic RNA synthesis. Collaboration aims to develop efficient and scalable methods for therapeutic oligonucleotide manufacturing with potential for future licensing.
  • MerckflagshipStrategic or Co-development Partner · 5 November 2025$37.8 million Supply Assurance Agreement plus Technology Transfer Agreement executed in Q4 2025. Represents major commercial validation of Codexis enzyme manufacturing capabilities.
  • Nitto Denko AveciacoreTechnology or Integration · 29 October 2025Evaluation agreement to explore Codexis ECO Synthesis Manufacturing Platform for therapeutic siRNA manufacturing. Collaboration aims to expand platform adoption and facilitate licensing discussions.

Scale indicators18 records

Recent moves8 records

Expansion highlights6 records

Codexis competitors and assessment

Company assessment

Direct peers

  • Twist Bioscience: Twist Bioscience is a leading DNA synthesis and synthetic biology provider serving pharma and biotech customers with high-throughput oligo production, broadly comparable to Codexis's nucleic acid manufacturing and enzyme-enabled service business.
  • Camena Bioscience: Camena Bioscience is building enzymatic DNA synthesis (gSynth) for high-fidelity gene and oligonucleotide manufacturing, overlapping with Codexis's ECO Synthesis value proposition for scalable, sustainable nucleic acid production.
  • Nitto Denko Avecia: Avecia (Nitto Denko Avecia) is a CDMO specializing in therapeutic oligonucleotide manufacturing (including siRNA), making it both a partner evaluating ECO Synthesis and a direct manufacturing-services competitor in RNA therapeutics.
  • DNA Script: DNA Script develops enzymatic DNA and RNA synthesis platforms (Syntax platform) targeting research and therapeutic oligo manufacturing, directly competing with Codexis's ECO Synthesis on enzymatic synthesis speed, length, and quality.
  • Ansa Biotechnologies: Ansa Biotechnologies is developing enzymatic DNA synthesis technology aimed at long, high-fidelity oligonucleotide assembly, directly competing with Codexis's ECO Synthesis platform on enzymatic nucleic acid manufacturing for therapeutics.
  • GenScript Biotech: GenScript provides gene synthesis, oligonucleotide manufacturing, and protein/biocatalysis services to pharma and biotech customers, comparable to Codexis's tailored enzymes, screening kits, and custom oligo manufacturing offerings.
  • Axolabs: Axolabs is a CDMO focused on oligonucleotide-based therapeutics (siRNA, antisense, aptamers) and recently signed an evaluation agreement with Codexis; it is a direct peer in commercial-scale therapeutic RNA manufacturing services.
  • Molecular Assemblies: Molecular Assemblies is pioneering terminator-free enzymatic DNA synthesis using proprietary polymerases, pursuing the same enzymatic alternative-to-SPOS positioning as Codexis's ECO Synthesis platform for therapeutic and synthetic biology applications.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher operates a global life sciences tools and pharma services/CDMO business (including oligonucleotide manufacturing through Patheon), making it a broad incumbent competing with Codexis in nucleic acid manufacturing and pharmaceutical services.
  • Novonesis (formerly Novozymes): Novonesis is a global enzyme engineering and production leader; while focused on industrial enzymes, its scale in protein engineering provides a broad competitive reference point for Codexis's CodeEvolver-driven enzyme business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Codexis social profiles

Digital presence

Codexis compliance and trust

Trust signal

Compliance2 records

Codexis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Codexis leadership team

Management profile

Number of profiles

Profiles7 records

Codexis funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Codexis M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codexis

What does Codexis do?

Codexis engineers custom enzymes and provides manufacturing services for pharmaceuticals using two proprietary platforms: the CodeEvolver enzyme engineering platform (ML-driven protein optimization) and the ECO Synthesis enzymatic RNA manufacturing platform. The company sells off-the-shelf enzyme screening kits, delivers tailored enzyme engineering and scale-up services for pharmaceutical API biocatalysis, and provides RNA manufacturing services (sequential enzymatic synthesis and ligation-based assembly) for therapeutic oligonucleotides including siRNA, gRNA, and ASOs.

Is Codexis a public or private company?

Codexis is a public company. It is classified as public and is currently operating.

When was Codexis founded?

Codexis was founded in 2002. It employs 101 to 250 people.

Where is Codexis based?

Codexis is headquartered in Redwood City, United States, in the North America region.

How does Codexis make money?

Four revenue lines are on record. RNA Manufacturing Services are the primary driver. The others are enzyme Products and Biocatalysis Services, technology Licensing and Transfer and supply Assurance Agreements.

Who are Codexis's main competitors?

Direct peers on record are Twist Bioscience, Camena Bioscience, Nitto Denko Avecia, DNA Script, Ansa Biotechnologies, GenScript Biotech, Axolabs and Molecular Assemblies. Broad incumbents are Thermo Fisher Scientific and Novonesis (formerly Novozymes).

Does Codexis have an API?

No public API is recorded for Codexis.

What industry is Codexis in?

Codexis's product category is Enzyme Biocatalysis Services. Its primary akta.pro industry code is HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaCodexis reiterates $72M-$76M 2026 revenue outlook while extending cash runway through 2028Codexis reported Q3 2026 revenue of $19.3 million and reiterated its 2026 revenue guidance of $72 million to $76 million. The company extended its cash runway through 2028 after raising $25 million in equity and taking a $60 million term loan. Management also highlighted ECO Synthesis scale-up to 100 grams and a pilot-scale technology transfer.Seeking AlphaCodexis, Inc. (CDXS) Q3 2026 Earnings Call TranscriptCodexis held its Q3 2026 earnings call on November 12, 2026, with CFO Georgia Erbez and CEO Alison Moore leading. Management provided forward-looking statements on 2026 revenue guidance, milestones, and product launches, but did not disclose specific financial figures.YahooCodexis (CDXS) Reports Q3 Loss, Beats Revenue EstimatesCodexis reported a Q3 loss of $0.08 per share, beating the consensus estimate of $0.09, and posted revenue of $19.26 million, up 4.16% from the estimate. The company has surpassed consensus EPS estimates four times in the last four quarters. Management's commentary on the earnings call will influence near-term stock movement.Defense WorldComparing Codexis (NASDAQ:CDXS) and Bionano Genomics (NASDAQ:BNGO)Codexis and Bionano Genomics are compared on institutional ownership, volatility, earnings, and analyst ratings. Codexis has higher institutional ownership (78.5% vs 11.3%) and lower beta (2.38 vs 1.73), but Bionano reports higher earnings. Analysts rate Codexis more favorably with a higher consensus target price.American Banking and Market NewsCodexis (CDXS) Projected to Post Earnings on ThursdayCodexis is expected to report Q3 2026 earnings on Thursday, November 12th, with analysts projecting a loss of $0.0957 per share and revenue of $18.72 million. The company's stock opened at $1.00, and the consensus rating is Hold with an average price target of $6.50.MarketScreenerCodexis, Inc. announced that it expects to receive $60 million in fundingCodexis, Inc. announced a $60 million funding round on November 10, 2026, with $42.5 million received in the first tranche. The round includes a senior secured term loan from new lender Trinity Capital, with 48 months of interest-only payments followed by a 12-month amortization period starting November 2030.American Banking and Market NewsContrasting Codexis (NASDAQ:CDXS) & Illumina (NASDAQ:ILMN)Codexis and Illumina are compared on institutional ownership, analyst ratings, revenue, and profitability. Illumina has higher revenue and earnings, but Codexis shows a higher potential upside from analyst price targets. Illumina beats Codexis on 11 of 14 factors.MarketBeatCodexis (CDXS) Projected to Post Quarterly Earnings on ThursdayCodexis is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $0.0957 per share and revenue of $18.72 million. The company's stock opened at $1.26, and analysts have an average rating of Hold with a consensus target price of $6.50.MarketBeatCodexis, Inc. $CDXS Stock Position Trimmed by Assenagon Asset Management S.A.Assenagon Asset Management S.A. trimmed its Codexis stake by 63.8% in Q3, selling 815,151 shares and holding 463,055 shares. Codexis reported Q2 EPS of -$0.13, beating estimates, with revenue of $14.91 million. Analysts have a consensus 'Hold' rating with a $6.50 price target.American Banking and Market NewsCodexis, Inc. $CDXS Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management cut its Codexis stake by 63.8% in Q3, selling 815,151 shares and leaving 463,055 shares worth $644,000. Other funds like BlackRock and Algert Global also adjusted positions, while Codexis reported Q2 EPS of -$0.13, beating estimates. Analysts hold a consensus 'Hold' rating with a $6.50 price target.